

Influvac[®] 2009 (southern hemisphere)
Composition according to recommendations by WHO and TGA (Australia)

The composition of Influvac[®] 2009, Solvay Biologicals' influenza vaccine for the influenza season 2009 in the southern hemisphere is as follows:

A/Brisbane/59/2007 (H1N1)-like strain (A/Brisbane/59/2007 IVR-148 reass.)	(15 µg haemagglutinin/dose)
A/ Brisbane/10/2007 (H3N2)-like strain (A/ Uruguay/716/2007 NYMC X-175C reass.)	(15 µg haemagglutinin/dose)
B/Florida/4/2006-like strain (B/Florida/4/2006)	(15 µg haemagglutinin/dose)

The recommendation of the World Health Organization for the composition of influenza virus vaccines for use in the 2009 season in the southern hemisphere as published in the Weekly Epidemiological Record, 10 October 2008, vol. **83**, 41 (pp 365-372):

- an A/Brisbane/59/2007 (H1N1)-like virus;
- an A/ Brisbane/10/2007 (H3N2)-like virus
- a B/Florida/4/2006-like virus

The recommendations of the Australian Influenza Vaccine Committee (AIVC) on Influenza Vaccines (published by the Therapeutic Goods Administration on 8 October 2008 – File No.: 2008/005990) for the strains suitable for the vaccine are as follows:

- H₁N₁ strain
A/Brisbane/59/2007 (IVR-148) is a suitable A/Brisbane/59/2007 (H1N1) - like strain.
- H₃N₂ strain
A/ Uruguay/716/2007 (NYMC X-175C) or A/Brisbane/10/2007 (IVR-147) is a suitable A/Brisbane/10/2007 (H3N2) - like strain
- B strain
B/Florida/4/2006 or B/Brisbane/3/2007 is a suitable B/Florida/4/2006-like strain

Global Regulatory Affairs, Liaison Vaccines
Weesp, 10 October 2008